Diagnosis, Staging and Treatment of Patients with Prostate Cancer

Objectives

National Clinical Guideline No. 8 provides Ireland’s evidence-based national framework for the diagnosis, staging and treatment of adults with newly diagnosed prostate cancer and adults with prostate-cancer metastases. It forms part of the National Cancer Control Programme’s wider remit to prevent cancer, improve treatment, survival and quality of life, and to promote consistent, safe and cost-effective care.[1][2][3]

• Improve clinical decision-making, patient outcomes, quality of life, consistency and standards of care, while reducing morbidity and mortality where possible.[2]
• Apply the best available research evidence alongside clinical expertise, particularly in areas of uncertainty, variation in practice, emerging evidence or potentially high impact.[4]
• Cover the full clinical pathway across risk classification, radiology and diagnosis, pathology, active surveillance, surgery, medical oncology, radiation oncology and palliative care.[5]
• Stratify patients as low, intermediate, high or very-high risk using clinical stage, Gleason score and prostate-specific antigen level, while keeping classification under review as evidence develops.[6][7]
• Offer active surveillance to appropriately selected men at the lowest risk of progression for whom radical treatment would otherwise be suitable, supported by multiparametric magnetic resonance imaging and repeat biopsy before or during enrolment.[8][9][10]
• Match radical treatment, including radical prostatectomy, radiotherapy, hormonal therapy and lymph-node dissection, to risk category, life expectancy, co-morbidity and informed patient preference.[11][12][13]
• Provide risk-adapted treatment for recurrent, metastatic and castration-resistant disease, including androgen-deprivation therapy, systemic therapies, bone-targeted treatment and radiotherapy where clinically indicated.[14][15][16]
• Introduce palliative care early, assess needs throughout illness and prevent or relieve suffering while supporting patients and families.[17][18]

Implementation

Implementation combines multidisciplinary acute-hospital care, nationally governed evidence-based recommendations, local service planning and behaviour-change methods. The National Cancer Control Programme, part of the Health Service Executive, developed and funded the guideline independently of funder influence, under National Clinical Effectiveness Committee endorsement and quality-assurance arrangements.[1][19][20]

• Deliver care through multidisciplinary teams involving relevant disciplines such as radiology, pathology, urology, medical oncology, radiation oncology and palliative care; discuss every patient at a multidisciplinary meeting, including consultation with both a urologist and radiation oncologist.[2][7]
• Assign corporate responsibility for implementation to each hospital Chief Executive Officer, General Manager and Clinical Director, while making multidisciplinary team members responsible for recommendations within their professional discipline.[3][6]
• Nominate a prostate cancer lead clinician in each prostate unit at designated cancer centres, agree prostate-care priorities annually through the National Cancer Control Programme, and incorporate guideline delivery into Health Service Executive service planning.[21]
• Develop recommendations through structured clinical questions, systematic literature searches, critical appraisal, evidence grading and consideration of applicability to Ireland, health-system impact, patient benefits, harms and resource implications.[20][22]
• Maintain transparent governance through conflict-of-interest declarations, patient advocacy, national stakeholder review, international expert review and documented consideration of feedback and amendments.[5][22][23]
• Use the Capability, Opportunity and Motivation Behaviour model and the Behaviour Change Wheel to identify implementation barriers and facilitators, select interventions such as education, training, enablement or environmental restructuring, and avoid unnecessary intervention where practice already meets recommendations.[24]
• Disseminate guidance through professional networks and National Cancer Control Programme and National Clinical Effectiveness Committee websites, supported by implementation tools, referral guidance, patient information and accompanying clinical documents.[21][25][26]
• Standardise diagnostic and pathology processes through site-specific biopsy reporting, structured prostatectomy datasets, Gleason scoring, tumour-extent reporting, margin reporting and documentation of extraprostatic extension.[27][28][29]
• Provide specialist follow-up for active surveillance using prostate-specific antigen testing, digital rectal examination, repeat biopsy and magnetic resonance imaging, and consider treatment conversion for clinical, pathological, imaging-based or patient-preference reasons.[30][31]
• Monitor implementation and patient outcomes through audit criteria, annual multidisciplinary Cancer Quality and Audit Fora, quarterly National Cancer Control Programme engagement with cancer centres, and periodic National Clinical Effectiveness Committee reporting.[19][3][21][26]
• Track selected access and timeliness measures, including rapid-access prostate-clinic appointments within 20 working days of referral, biopsy histology reports within 10 working days in 80% of cases, surgical treatment within 30 working days of decision to treat, multidisciplinary discussion for all diagnosed patients, and radical radiotherapy within 15 working days of readiness for treatment.[26]
• Review the literature base periodically and subject substantive updates to National Clinical Effectiveness Committee approval; the guideline was intended for review three years after publication, with interim updates as required.[21]
• Seek additional implementation resources through the Health Service Executive service-planning process where needed, particularly for imaging, biopsy capacity, pathology, radiology, specialist follow-up, equipment and staff training.[21][32][30]

Monitoring & Evaluation

Monitoring combines national governance, implementation audit, clinical surveillance and structured reporting. The National Clinical Effectiveness Committee reports periodically on guideline implementation and impact, reports on National Clinical Audit performance, and publishes an annual report.[19]The National Cancer Control Programme undertakes periodic surveillance of the literature, with guideline review considered three years after publication and updates requiring National Clinical Effectiveness Committee approval.[21]

• Audit implementation and patient outcomes against audit criteria to assess effects on patient care.[21][26]
• Monitor cancer-centre performance and service planning through quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each cancer centre.[21]
• Develop key performance indicators through the Prostate National Clinical Lead's Network and organise annual multidisciplinary Cancer Quality and Audit Fora.[3]
• Monitor timely access through appointments at rapid-access prostate clinics within 20 working days of referral, surgery within 30 working days of a decision to treat, biopsy histology reporting within 10 working days in 80% of cases, and radical radiotherapy within 15 working days of readiness for treatment.[26]
• Confirm that all people diagnosed with prostate cancer are discussed at a multidisciplinary team meeting.[26]
• Monitor active surveillance using prostate-specific antigen, digital rectal examination, repeat biopsy, Gleason grade, tumour volume or positive-core changes, magnetic resonance imaging findings and patient preference as potential triggers for treatment conversion.[33][31]
• Use ultrasensitive prostate-specific antigen testing after radical prostatectomy and offer early salvage radiotherapy when prostate-specific antigen becomes detectable in appropriate patients.[34]
• Apply structured pathology reporting, external quality assurance and minimum datasets for biopsies and prostatectomy specimens to support completeness, clinical accountability and audit.[35][36][37]
• Monitor safety before each bisphosphonate or denosumab dose through serum creatinine, electrolytes and calcium, and monitor for hypocalcaemia, nephrotoxicity and osteonecrosis of the jaw.[16][38]

Corporate responsibility for implementation rests with hospital Chief Executive Officers, General Managers and Clinical Directors, while multidisciplinary team members are responsible for discipline-specific recommendations.[21]Clinical staff are expected to comply with professional and competence requirements for prostate cancer care.[21]The document does not specify a complete consolidated indicator set, national surveillance registry, final audit measures or comprehensive reporting timetable beyond the stated mechanisms.[3][26]

Costing & Financing

The guideline was commissioned and funded by the National Cancer Control Programme, independently of the funding body, but it does not specify an overall implementation budget, dedicated allocation, funding gap or resource-mobilisation plan.[20]Many recommendations reflect current practice and are considered cost neutral, while additional resources can be sought through the Health Service Executive service-planning process.[21]

• Recognise substantial cancer-related economic burden, including estimated European Union cancer costs of 126 billion euros in 2009 and Irish cancer-related healthcare costs of 619 million euros.[4]
• Plan for demand growth, as cancer incidence is projected to rise by 99% by 2040, with potentially material consequences for prostate cancer costs.[4]
• Provide additional capacity for magnetic resonance imaging, targeted and transperineal biopsy, outpatient care, theatre time, anaesthesia, pathology, radiology and workforce training where required.[32][30][31]
• Consider that active surveillance may increase follow-up, biopsy and magnetic resonance imaging activity, but anticipated savings from fewer radical treatments may offset these costs.[30]
• Recognise that upgrading the cyclotron at the Blackrock clinic would require substantial investment.[39]
• Use conventional Irish cost-effectiveness reference values of 20,000 to 45,000 euros per quality-adjusted life year for non-drug interventions, while noting that no explicit threshold exists.[40][41]
• Apply the stated five-year follow-up cost of 1,430.18 euros per patient, or 1,161,306.10 euros for 812 annually diagnosed prostate cancers, where the specified pathway applies.[42]
• Use established Health Service Executive pricing and reimbursement processes for cancer medicines, incorporating budget impact, public resources, pharmacoeconomic assessment and company submissions.[42]

Economic evidence supports some specific choices but remains context-dependent: denosumab was considered cost-effective relative to zoledronic acid in 2011, although later price changes suggested zoledronic acid was likely to be the more cost-effective option.[38]High-dose-rate brachytherapy combined with external beam radiotherapy was modelled as cost-effective, though applicability of the clinical evidence was limited.[43][44]The document does not provide comprehensive drug prices, national budget-impact estimates or quantified funding gaps.[42]